Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Assertio Therapeutics Inc (ASRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ASRT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $2.8
Year Target Price $2.8
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.39% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 62.15M USD | Price to earnings Ratio - | 1Y Target Price 2.8 |
Price to earnings Ratio - | 1Y Target Price 2.8 | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.51 - 1.80 | Updated Date 06/29/2025 |
52 Weeks Range 0.51 - 1.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -25.72% | Operating Margin (TTM) -48.87% |
Management Effectiveness
Return on Assets (TTM) -6.6% | Return on Equity (TTM) -25.19% |
Valuation
Trailing PE - | Forward PE 14.99 | Enterprise Value 14646122 | Price to Sales(TTM) 0.52 |
Enterprise Value 14646122 | Price to Sales(TTM) 0.52 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 9.42 | Shares Outstanding 95780704 | Shares Floating 85543695 |
Shares Outstanding 95780704 | Shares Floating 85543695 | ||
Percent Insiders 2.52 | Percent Institutions 27.05 |
Analyst Ratings
Rating 4.5 | Target Price 2.8 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Assertio Therapeutics Inc
Company Overview
History and Background
Assertio Therapeutics, Inc., founded in 1995, has evolved through various name changes and strategic shifts, initially focusing on niche pharmaceuticals and later expanding through acquisitions. It has navigated financial challenges and restructured to focus on specific therapeutic areas.
Core Business Areas
- Neurology: Focuses on treatments for neurological conditions, including pain management and related disorders.
- Pain and Inflammation: Develops and commercializes products targeting pain and inflammation, with a focus on non-opioid solutions.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives. The organizational structure is typical of a specialty pharmaceutical company, with departments focused on research and development, sales and marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Cambia: A nonsteroidal anti-inflammatory drug (NSAID) used to treat acute migraine attacks. Competitors include other NSAIDs and triptans like Imitrex (GSK), Maxalt (MRK), and Relpax (PFE). Revenue data is proprietary, market share is estimated to be small.
- Indocin: A nonsteroidal anti-inflammatory drug (NSAID) used for various inflammatory conditions. Competitors include other generic NSAIDs like ibuprofen and naproxen. Revenue data is proprietary, market share is estimated to be small.
- Otrexup: Otrexup is a subcutaneous auto-injector containing methotrexate used to treat adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. Competitors include injectable methotrexate. Revenue data is proprietary, market share is estimated to be small.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Companies face pressure to develop innovative products and manage patent expirations.
Positioning
Assertio Therapeutics is positioned as a specialty pharmaceutical company focused on acquiring, developing, and commercializing differentiated products. Its competitive advantage lies in its focused approach and strategic acquisitions.
Total Addressable Market (TAM)
The TAM for pain management and neurology is significant, estimated at billions of dollars annually. Assertio's position within this TAM is niche, targeting specific patient populations and therapeutic areas.
Upturn SWOT Analysis
Strengths
- Specialty pharmaceutical focus
- Experienced management team
- Established sales and marketing infrastructure
- Portfolio of approved products
Weaknesses
- Limited R&D pipeline
- Reliance on acquired products
- Small market share in competitive markets
- Dependence on a few key products for revenue
Opportunities
- Strategic acquisitions of complementary products
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Development of innovative drug delivery systems
Threats
- Generic competition
- Pricing pressures
- Regulatory changes
- Product liability litigation
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- GSK
- MRK
- PFE
Competitive Landscape
Assertio competes with larger pharmaceutical companies. Its advantages include its niche focus and experienced sales force. Disadvantages include limited R&D and smaller market share.
Major Acquisitions
Acquired Company Name
- Year: 2020
- Acquisition Price (USD millions): 27
- Strategic Rationale: Acquisition of FDA-approved products from Iroko Pharmaceuticals
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 75
- Strategic Rationale: Acquisition of Sympazan assets.
Growth Trajectory and Initiatives
Historical Growth: Assertio's historical growth has been driven by acquisitions and product launches. Growth has been uneven due to financial restructuring and market changes.
Future Projections: Future growth projections depend on successful product commercialization and strategic initiatives. Analyst estimates vary based on market conditions.
Recent Initiatives: Recent initiatives focus on optimizing the product portfolio and reducing operating expenses. This includes strategic acquisitions and divestitures.
Summary
Assertio Therapeutics is a specialty pharmaceutical company with a focus on neurology and pain. While it has a portfolio of approved products and an experienced team, its limited R&D pipeline and reliance on acquisitions pose challenges. Strategic initiatives to optimize the portfolio and reduce expenses are crucial for future success. Maintaining focus is essential amidst market competition and patent expiries.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assertio Therapeutics Inc
Exchange NASDAQ | Headquaters Lake Forest, IL, United States | ||
IPO Launch date 1997-11-05 | CEO & Director Mr. Brendan P. O'Grady | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 58 | Website https://www.assertiotx.com |
Full time employees 58 | Website https://www.assertiotx.com | ||
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.